Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) EBITDA (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed EBITDA for 2 consecutive years, with -$15.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 50.38% to -$15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$55.0 million through Dec 2025, down 237.74% year-over-year, with the annual reading at -$55.0 million for FY2025, 237.74% down from the prior year.
  • EBITDA hit -$15.0 million in Q4 2025 for Connect Biopharma Holdings, up from -$17.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $14.9 million in Q2 2024 to a low of -$17.1 million in Q3 2025.